Zoetis Inc. (NYSE:ZTS) Shares Bought by Magnetar Financial LLC

Magnetar Financial LLC grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 38.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,408 shares of the company's stock after buying an additional 9,471 shares during the period. Magnetar Financial LLC's holdings in Zoetis were worth $5,606,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC grew its position in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. lifted its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Zoetis during the 3rd quarter worth $31,000. Dunhill Financial LLC increased its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Asset Planning Inc acquired a new stake in shares of Zoetis during the 4th quarter worth about $58,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Buying and Selling

In other news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,862 shares of company stock worth $312,254. Corporate insiders own 0.16% of the company's stock.

Remove Ads

Zoetis Stock Up 0.1 %

ZTS traded up $0.19 on Monday, hitting $163.22. 1,817,407 shares of the company were exchanged, compared to its average volume of 2,499,361. The firm has a 50-day moving average price of $166.70 and a two-hundred day moving average price of $175.22. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company has a market cap of $73.09 billion, a price-to-earnings ratio of 29.84, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. Zoetis's payout ratio is 36.56%.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent analyst reports. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective on the stock. Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Barclays boosted their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Finally, UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price target for the company. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.